{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=43", "query": { "condition": "Advanced Cancer", "page": 43 }, "page_size": 10 }, "pagination": { "page": 43, "page_size": 10, "total_count": 9795, "total_pages": 980, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=44&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cancer&page=42&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T00:53:16.455Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01840592", "title": "Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2013-04", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01840592" }, { "nct_id": "NCT00831792", "title": "TKI258 in Castrate Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "TK1258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 46, "start_date": "2010-04-07", "completion_date": "2017-06-12", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00831792" }, { "nct_id": "NCT02527434", "title": "Study of Tremelimumab in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Bladder Cancer", "Triple-negative Breast Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Tremelimumab monotherapy", "type": "BIOLOGICAL" }, { "name": "MEDI4736 monotherapy", "type": "BIOLOGICAL" }, { "name": "MEDI4736 + tremelimumab combination therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "150 Years", "sex": "ALL", "summary": "18 Years to 150 Years" }, "enrollment_count": 64, "start_date": "2015-11-02", "completion_date": "2023-03-28", "has_results": true, "last_update_posted_date": "2023-11-15", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 3, "location_summary": "San Francisco, California • Memphis, Tennessee • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02527434" }, { "nct_id": "NCT07527858", "title": "Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Microsatellite Stable Colorectal Cancer" ], "interventions": [ { "name": "Denikitug", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Trifluridine-Tipiracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2026-05-19", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 6, "location_summary": "North Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "North Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07527858" }, { "nct_id": "NCT04534283", "title": "A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Cancer Metastatic", "BRAF V600E", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "ERK Mutation", "RAF1 Gene Mutation" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "LY3214996", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anita Turk", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-10-05", "completion_date": "2023-08-07", "has_results": true, "last_update_posted_date": "2024-08-07", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04534283" }, { "nct_id": "NCT03690141", "title": "An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castrate-resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "eFT508", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 16, "start_date": "2018-11-27", "completion_date": "2020-04-27", "has_results": true, "last_update_posted_date": "2024-06-21", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03690141" }, { "nct_id": "NCT05660083", "title": "Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-negative Breast Cancer", "Metastatic Breast Cancer", "Metaplastic Breast Carcinoma", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-01-12", "completion_date": "2028-12-02", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660083" }, { "nct_id": "NCT06760481", "title": "Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies" ], "interventions": [ { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2025-04-13", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760481" }, { "nct_id": "NCT00020644", "title": "Continuous Infusion Gemcitabine in Treating Patients With Advanced Metastatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advocate Lutheran General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-07", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020644" }, { "nct_id": "NCT00982696", "title": "Treatment of Advanced Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell of Head and Neck" ], "interventions": [ { "name": "Opioid Growth Factor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2008-02", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2014-09-30", "last_synced_at": "2026-10-26T00:53:16.455Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00982696" } ] }